PUBLICATIONS

25-05-2010

Derry Ridgway, MD, Maciej Sopata, MD, PhD, Arvydas Burneckis, MD, Lillian Jespersen, MSc, and Christine Andersen, MSc
CLINICAL EFFICACY AND SAFETY OF ONCE-DAILY DOSING OF A NOVEL, PROLONGED-RELEASE ORAL MORPHINE TABLET COMPARED WITH TWICE-DAILY DOSING OF A STANDARD CONTROLLED-RELEASE MORPHINE TABLET IN PATIENTS WITH CANCER PAIN: A Randomized, Double-Blind, Exploratory Crossover Study
Journal of Pain and Symptom Management, April 2010, Volume 39 Number 4

01-10-2006

Washington N, Wilson CG. EROSION VERSUS DIFFUSION - THE FUTURE FOR CONTROLLED & SUSTAINED DRUG DELIVERY
Drug Delivery Technology 2006;6(9):71-74

01-05-2006

Washington N, Wilson CG. CAN ORAL CONTROLLED DRUG DELIVERY MEET THE CHALLENGES POSED BY CHRONOTHERAPEUTICS?
Drug Delivery Technology 2006;6(6):57-59

01-05-2004

Marvola J, Kanerva H, Slot L, Lipponen M, Kekki T, Hietanen H et al. NEUTRON ACTIVATION-BASED GAMMA SCINTIGRAPHY IN PHARMACOSCINTIGRAPHIC EVALUATION OF AN EGALET CONSTANT-RELEASE DRUG DELIVERY SYSTEM.
Int J Pharm 2004;281 (1-2):3-10

Olsen M.R., Lindhardt K., Øvergård J.M., Haahr A.-M., Hemmingsen P.H., Lyhne-Iversen L.I.: Influence of Composition and Geometry on Chewability of Egalet® ADPREM Tablets
(PPT) Presented at the 2009 Controlled Release Society Conference

Christensen L.H. Nilsson M.S., Hemmingsen P.H., Tygesen P.: Drug Delivery on Time by Egalet® CHRONO Technology
(PDF) Poster presented at the 2009 AAPS Annual Meeting And Exposition, Los Angeles

Egalet® morphine, a Once-a-day, Abuse Resistant Opioid Analgesics: a Double-Blind, Randomized, Cross-over Efficacy Study in Cancer Patients
(PDF) J Pain 2009; 10(4) supp 1; S36 (Poster No. 246)

Recreational Drug User Preferences: Egalet® Opioids have low Abuse and Tampering Attractiveness relative to Marketed Opioids
(PDF) J Pain 2009; 10(4) supp 1; S60, (Poster No. 342)

Drug Abuse Resistant, Controlled release, using Egalet® Dosage Units
(PDF) CRS 2007, July 7-11 (Poster No. 680)

Metz H, Bar-Shalom D, Hemmingsen PH, Fischer G, Mäder K. EPR AND NMR IMAGING IN MONITORING THE RELEASE MECHANISMS FROM EGALET® DOSAGE UNITS
(PDF) Poster presented at the Controlled Release Society, Vienna, Austria; 2006

Egalet and RedHill Biopharma enter into an Exclusive License Agreement

Egalet Corporate Presentation 2010

01-04-2006

Pedersen AV. NYE FORBEDREDE ORALE DOSERINGSFORMER FOR LÆGEMIDLER UDVIKLES I DANMARK
BioZoom 2006;4:38-40

01-06-2006

Egalet: A WORLD LEADER IN EROSION-BASED THERAPEUTICS
Drug Delivery Technology 2006;6(8):60-61

01-11-2006

Pedersen AV, Hemmingsen PH. EROSION-BASED DRUG DELIVERY.
Manufacturing Chemist 2006 Nov.